African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates

Journal of Virology

Volumn 88, Issue 14, 2014, Pages 8139-8152

  Matsuoka, Yumiko ^a   Suguitan Jr , Amorsolo ^a,c   Orandle, Marlene ^a   Paskel, Myeisha ^a   Boonnak, Kobporn ^a,d   Gardner, Donald J ^a   Feldmann, Friederike ^a   Feldmann, Heinz ^a   Marino, Michael ^a,e   Jin, Hong ^b   Kemble, George ^b,f   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MEDIMMUNE   (United States)

^c American University of the Caribbean   (Netherlands)

^d MAHIDOL UNIVERSITY   (Thailand)

^e CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^f 3 V Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LECTIN; NEUTRALIZING ANTIBODY; RECEPTOR; SIALIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCHEMISTRY; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H6N1; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H9N2; MALE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RESPIRATORY SYSTEM; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; PRIMATE DISEASES; RESPIRATORY SYSTEM; VACCINES, ATTENUATED;

EID: 84904658491     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00425-14     Document Type: Article

References (64)

1. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396. http://dx.doi.org/10.1126/science.279.5349.393.
2. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY, Guan Y. 2004. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363:617-619. http: //dx.doi.org/10.1016/S0140-6736(04)15595-5.
3. WHO. 19 February 2003, posting date. Influenza A (H5N1) in Hong Kong Special Administrative Region of China. WHO, Geneva, Switzerland. http://www.who.int/csr/don/2003_2_19/en/.
4. WHO. 14 January 2004, posting date. Avian influenza A(H5N1) in humans in Viet Nam and poultry in Asia-update. WHO, Geneva, Switzerland. http://www.who.int/csr/don/2004_01_14/en/.
5. WHO. 23 January 2004, posting date. Avian influenza A (H5N1) in humans in Thailand-update 6. WHO, Geneva, Switzerland. http://www.who.int/csr/don/2004_01_23/en/.
6. WHO. 2013. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. WHO, Geneva, Switzerland.
7. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD. 2004. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. U. S. A. 101:1356-1361. http://dx.doi.org/10.1073/pnas.0308352100.
8. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat Vennema HH, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A. 2004. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587-593. http://dx.doi.org/10.1016/S0140-6736(04)15589-X.
9. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS, Guan Y. 2005. Human infection with an avian H9N2 influenzaAvirus in Hong Kong in 2003. J. Clin. Microbiol. 43:5760-5767. http://dx.doi.org/10.1128/JCM.43.11.5760-5767.2005.
10. Guo Y, Li J, Cheng X. 1999. Discovery of men infected by avian influenza A (H9N2) virus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 13:105-108. (In Chinese.)
11. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF. 1999. Human infection with influenza H9N2. Lancet 354: 916-917. http://dx.doi.org/10.1016/S0140-6736(99)03311-5.
12. Karron RA, Talaat K, Luke C, Callahan K, Thumar B, Dilorenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K, Chen G, Lamirande E, Coelingh K, Jin H, Murphy BR, Kemble G, Subbarao K. 2009. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27:4953-4960. http://dx.doi.org/10.1016/j.vaccine.2009.05.099.
13. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664. http://dx.doi.org/10.1016/S0140-6736(06)68656-X.
14. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351. http://dx.doi.org/10.1056/NEJMoa055778.
15. Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, Chen GL, Lamirande EW, Jin H, Coelingh KL, Murphy BR, Kemble G, Subbarao K. 2009. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 27:3744-3753. http://dx.doi.org/10.1016/j.vaccine.2009.03.082.
16. Couch RB, Patel SM, Wade-Bowers CL, Nino D. 2012. A randomized clinical trial of an inactivated avian influenzaA(H7N7) vaccine. PLoS One 7:e49704. http://dx.doi.org/10.1371/journal.pone.0049704.
17. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. 2006. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43:1135-1142. http://dx.doi.org/10.1086/508174.
18. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Wang X, Wood J, Feng Z, Wang Y, Yin W. 2006. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368:991-997. http://dx.doi.org/10.1016 /S0140-6736(06)69294-5.
19. Leroux-Roels I, Leroux-Roels G. 2009. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8:401-423. http://dx.doi.org/10.1586/erv.09.15.
20. Chen GL, Subbarao K. 2009. Live attenuated vaccines for pandemic influenza. Curr. Top. Microbiol. Immunol. 333:109-132. http://dx.doi.org/10.1007/978-3-540-92165-3_5.
21. Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Hoschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC. 2008. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenzaA(H5N1) vaccine in healthy adults. Vaccine 26:4160-4167. http://dx.doi.org/10.1016/j.vaccine.2008.05.077.
22. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. 2008. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198:642-649. http://dx.doi.org/10.1086/590913.
23. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. 2007. Antigen sparing and crossreactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. http: //dx.doi.org/10.1016/S0140-6736(07)61297-5.
24. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M. 2000. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136:168-175. http://dx.doi.org/10.1016/S0022-3476(00)70097-7.
25. Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K, Palladino G, Lee MS, Razmpour A, Stoddard J, Forrest BD. 2004. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J. 23:1053-1055. http://dx.doi.org/10.1097/01.inf.0000143643.44463.b1.
26. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160.
27. Kendal AP. 1997. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 13:591-609. http://dx.doi.org/10.1023/A:1007327505862.
28. Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, et al. 1993. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J. Infect. Dis. 168:881-887. http://dx.doi.org/10.1093/infdis/168.4.881.
29. Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. 2009. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J. Infect. Dis. 199:711-716. http://dx.doi.org/10.1086/596558.
30. Talaat KR, Karron RA, Luke CJ, Thumar B, McMahon BA, Chen GL, Lamirande EW, Jin H, Coelingh KL, Kemble G, Subbarao K. 2011. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 29:3144-3148. http://dx.doi.org/10.1016/j.vaccine.2011.02.043.
31. Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K. 2008. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378:123-132. http://dx.doi.org/10.1016/j.virol.2008.05.021.
32. Suguitan AL, Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360. http://dx.doi.org/10.1371/journal.pmed.0030360.
33. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K. 2003. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21:4430-4436. http://dx.doi.org/10.1016/S0264-410X(03)00430-4.
34. Chen Z, Santos C, Aspelund A, Gillim-Ross L, Jin H, Kemble G, Subbarao K. 2009. Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets. J. Virol. 83:65-72. http://dx.doi.org/10.1128 /JVI.01775-08.
35. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. 2001. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J. Virol. 75:6687-6691. http://dx.doi.org/10.1128/JVI.75.14.6687-6691.2001.
36. Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Tong T, Zhong G, Song J, Zhang Y, Tian G, Guan Y, Xu XN, Bu Z, Kawaoka Y, Chen H. 2009. Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog. 5:e1000409. http://dx.doi.org/10.1371/journal.ppat.1000409.
37. Tolnay AE, Baskin CR, Tumpey TM, Sabourin PJ, Sabourin CL, Long JP, Pyles JA, Albrecht RA, Garcia-Sastre A, Katze MG, Bielefeldt-Ohmann H. 2010. Extrapulmonary tissue responses in cynomolgus macaques (Macaca fascicularis) infected with highly pathogenic avian influenza A (H5N1) virus. Arch. Virol. 155:905-914. http://dx.doi.org/10.1007 /s00705-010-0662-8.
38. Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD. 2003. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet. Pathol. 40:304-310. http://dx.doi.org/10.1354/vp.40-3-304.
39. Schaap-Nutt A, Higgins C, Amaro-Carambot E, Nolan SM, D'Angelo C, Murphy BR, Collins PL, Schmidt AC. 2011. Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates. J. Virol. 85:4007-4019. http://dx.doi.org/10.1128/JVI.02542-10.
40. Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH. 2005. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23:4631-4646. http: //dx.doi.org/10.1016/j.vaccine.2005.04.035.
41. Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. 2003. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647-3652. http://dx.doi.org/10.1016 /S0264-410X(03)00426-2.
42. McAuliffe J, Vogel L, Roberts A, Fahle G, Fischer S, Shieh WJ, Butler E, Zaki S, St Claire M, Murphy B, Subbarao K. 2004. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 330:8-15. http://dx.doi.org/10.1016/j.virol.2004.09.030.
43. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
44. Chen GL, Lau YF, Lamirande EW, McCall AW, Subbarao K. 2011. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc. Natl. Acad. Sci. U. S. A. 108:1140-1145. http://dx.doi.org/10.1073/pnas.1009908108.
45. Kuchipudi SV, Nelli R, White GA, Bain M, Chang KC, Dunham S. 2009. Differences in influenza virus receptors in chickens and ducks: implications for interspecies transmission. J. Mol. Genet. Med. 3:143-151. http://dx.doi.org/10.4172/1747-0862.1000026.
46. Geisler C, Jarvis DL. 2011. Effective glycoanalysis with Maackia amurensis lectins requires a clear understanding of their binding specificities. Glycobiology 21:988-993. http://dx.doi.org/10.1093/glycob/cwr080.
47. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. 2003. A primate model to study the pathogenesis of influenza A (H5N1) virus infection. Avian Dis. 47:931-933. http://dx.doi.org/10.1637/0005-2086-47.s3.931.
48. Baskin CR, García-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, Nistal-Villán E, Katze MG. 2004. Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J. Virol. 78:10420-10432. http://dx.doi.org /10.1128/JVI.78.19.10420-10432.2004.
49. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025. http://dx.doi.org/10.1038/nature08260.
50. Murphy BR, Sly DL, Tierney EL, Hosier NT, Massicot JG, London WT, Chanock RM, Webster RG, Hinshaw VS. 1982. Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science 218:1330-1332. http://dx.doi.org /10.1126/science.6183749.
51. Murphy BR, Hinshaw VS, Sly DL, London WT, Hosier NT, Wood FT, Webster RG, Chanock RM. 1982. Virulence of avian influenza A viruses for squirrel monkeys. Infect. Immun. 37:1119-1126.
52. Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG. 2009. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc. Natl. Acad. Sci. U. S. A. 106:3455-3460. http://dx.doi.org/10.1073/pnas.0813234106.
53. Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, Deng G, Zhu Q, Fan S, Makino A, Muramoto Y, Fukuyama S, Tamura D, Noda T, Eisfeld AJ, Katze MG, Chen H, Kawaoka Y. 2012. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J. Virol. 86:6055-6066. http://dx.doi.org/10.1128/JVI.00365-12.
54. Min JY, Vogel L, Matsuoka Y, Lu B, Swayne D, Jin H, Kemble G, Subbarao K. 2010. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J. Virol. 84:11950-11960. http://dx.doi.org /10.1128/JVI.01305-10.
55. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. 2006. Avian flu: influenza virus receptors in the human airway. Nature 440:435-436. http://dx.doi.org/10.1038/440435a.
56. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, Kwong DL, Wong MP, Chui WH, Poon LL, Tsao SW, Guan Y, Peiris JS. 2007. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat. Med. 13:147-149. http://dx.doi.org/10.1038/nm1529.
57. Nicholls JM, Bourne AJ, Chen H, Guan Y, Peiris JS. 2007. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir. Res. 8:73. http://dx.doi.org/10.1186/1465-9921-8-73.
58. Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. 2008. Evolving complexities of influenza virus and its receptors. Trends Microbiol. 16: 149-157. http://dx.doi.org/10.1016/j.tim.2008.01.008.
59. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. 2007. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am.J. Pathol. 171:1215-1223. http://dx.doi.org/10.2353/ajpath.2007.070248.
60. Thongratsakul S, Suzuki Y, Hiramatsu H, Sakpuaram T, Sirinarumitr T, Poolkhet C, Moonjit P, Yodsheewan R, Songserm T. 2010. Avian and human influenza A virus receptors in trachea and lung of animals. Asian Pac. J. Allergy Immunol. 28:294-301. http://apjai.digitaljournals.org/index.php /apjai/article/viewFile/353/340.
61. Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, Wilson IA. 2008. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J. Mol. Biol. 381:1382-1394. http://dx.doi.org/10.1016/j.jmb.2008.04.016.
62. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA. 2006. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 355:1143-1155. http://dx.doi.org/10.1016/j.jmb.2005.11.002.
63. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. 2006. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312:404-410. http://dx.doi.org/10.1126 /science.1124513.
64. Walther T, Karamanska R, Chan RW, Chan MC, Jia N, Air G, Hopton C, Wong MP, Dell A, Malik Peiris JS, Haslam SM, Nicholls JM. 2013. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog. 9:e1003223. http://dx.doi.org/10.1371/journal.ppat.1003223.